Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT314 + BNT327 + chemotherapy
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational combination therapy, developed by BioNTech SE in collaboration with Genmab and Bristol Myers Squibb, is designed for the treatment of microsatellite stable or mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). The regimen consists of two bispecific antibodies and standard chemotherapy. BNT314 (GEN1059) is a DuoBody-based bispecific antibody targeting EpCAM and the co-stimulatory receptor 4-1BB (CD137), intended to activate T cells within the tumor microenvironment. BNT327 (pumitamig) is a bispecific antibody targeting PD-L1 and VEGF-A, combining immune checkpoint blockade with anti-angiogenic activity. These biologics are administered intravenously alongside standard chemotherapy regimens such as FOLFIRI, mFOLFOX6, or CAPEOX. The combination is currently being evaluated in a Phase 1/2 clinical trial (NCT07079631) to overcome the typical immunotherapy resistance observed in MSS/pMMR colorectal tumors.
- Other names
- BNT314 + BNT327 + SoC chemotherapyBNT314 + BNT327 + FOLFIRIBNT314 + BNT327 + mFOLFOX6BNT314 + BNT327 + CAPEOX
02
Targets
EPCAM (Epithelial cell adhesion molecule)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)DNATNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on BNT314 + BNT327 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT314 + BNT327 + chemotherapy.